OncoTherapy Science, Inc. (FRA:30O)

OncoTherapy Science Ratios and Metrics

Market cap in millions EUR. Fiscal year is April - March.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb 23, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Market Capitalization	43	47	27	63	99	167
Market Cap Growth	3.28%	76.17%	-57.45%	-36.38%	-41.02%	80.71%
Enterprise Value	31	41	23	56	82	141
Last Close Price	0.09	0.15	0.10	0.30	0.50	0.93
PS Ratio	10.18	10.14	7.14	7.98	11.53	65.33
PB Ratio	3.73	10.45	12.33	10.60	6.72	7.05
P/TBV Ratio	3.73	10.45	12.33	10.60	6.72	7.06
EV/Sales Ratio	7.30	8.88	6.16	7.12	9.60	55.11
Net Debt / Equity Ratio	-1.02	-1.14	-1.49	-1.31	-0.93	-0.94
Net Debt / EBITDA Ratio	-	-	-	1.02	0.90	1.82
Net Debt / FCF Ratio	-	1.02	0.43	1.40	0.73	1.61
Asset Turnover	0.42	0.74	0.51	0.54	0.38	0.08
Inventory Turnover	14.20	16.60	17.04	10.97	20.37	51.97
Quick Ratio	7.97	2.85	1.99	2.04	3.70	15.73
Current Ratio	8.53	3.38	2.28	2.34	4.31	16.46
Return on Equity (ROE)	-59.41%	-150.79%	-213.42%	-78.93%	-101.74%	-40.02%
Return on Assets (ROA)	-26.73%	-49.27%	-58.87%	-32.98%	-42.40%	-24.21%
Return on Capital Employed (ROCE)	-36.20%	-96.30%	-220.50%	-122.70%	-98.70%	-51.60%
Earnings Yield	-11.04%	-10.71%	-29.59%	-12.35%	-19.34%	-7.20%
FCF Yield	-	-10.71%	-28.23%	-8.81%	-19.03%	-8.32%
Buyback Yield / Dilution	-21.55%	-22.73%	-10.45%	-2.76%	-6.31%	-8.14%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.